Skip to main content
Premium Trial:

Request an Annual Quote

Wellcome Trust Genotyping Study Using Agilent Arrays

NEW YORK (GenomeWeb News) – Agilent Technologies said today that the Wellcome Trust Case Control Consortium will use the firm’s custom-made, whole-genome copy number variation microarrays in the next phase of the genetic variation study.
 
Agilent is the third company to announce that the WTCCC is using its arrays for the second phase of the project. Previously, Illumina and Affymetrix both announced their technologies are being employed by researchers in the study.
 
The WTCCC is a group of UK researchers who began in 2005 studying thousands of genotyped human samples for genes associated with coronary heart disease, hypertension, types 1 and 2 diabetes, bipolar disorder, Crohn's disease, rheumatoid arthritis, tuberculosis, autoimmune thyroid disease, ankylosing spondylitis, multiple sclerosis, and breast cancer.
 
Agilent said that genetic samples will be processed by Oxford Gene Technology, which is a UK-based Agilent microarray certified service provider.
 
“This is an important new study of human genetic variation in common disease for which we require high-resolution microarrays with extremely reproducible performance,” said Matthew Hurles of the Wellcome Trust Sanger Institute.
 
Financial terms of the agreement were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.